Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
2 Months : From Dec 2019 to Feb 2020
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit Thursday said the European Commission approved its Spravato nasal spray for adults with treatment-resistant major depressive disorder.
The drug maker said the approval covers Spravato in combination with a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor for adults with treatment-resistant depression, meaning they haven't responded to at least two different treatments.
Janssen said major depressive disorder affects about 40 million people across Europe and is the leading cause of disability worldwide.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
December 19, 2019 06:17 ET (11:17 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.